Current Headlines

  1. OMEICOS Receives BMBF Research Grant To Advance Its Novel Approach To Treat Atrial Fibrillation

    OMEICOS Therapeutics, a biopharmaceutical company developing first-in-class small molecule therapeutics for the prevention and treatment of cardiovascular diseases including atrial fibrillation, recently announced the approval of an approximately €1.7M grant by the German Ministry of Education and Research (BMBF)

  2. Eurofins Pharma Discovery Services Launches New eCommerce Platform For Drug Discovery Products

    Eurofins Pharma Discovery Services announces the launch of web-based ordering with its new eCommerce platform, which enables researchers and drug discovery scientists to order the highest quality kits, protein, enzymes and cell-based reagents directly through the web

  3. Tyme Technologies, Inc. Receives FDA Acceptance Of Investigational New Drug Application For Oncology Drug Candidate, SM-88

    Tyme Technologies, Inc., a research and development company operating through its wholly-owned subsidiary, Tyme Inc., focused on development and eventual commercialization of oncology products, announced recently that the U.S

  4. Vertex And CRISPR Therapeutics Establish Collaboration To Use CRISPR-Cas9 Gene Editing Technology To Discover And Develop New Treatments For Genetic Diseases

    Vertex Pharmaceuticals Incorporated and CRISPR Therapeutics recently announced that the two companies have entered into a strategic research collaboration focused on the use of CRISPR’s gene editing technology, known as CRISPR-Cas9, to discover and develop potential new treatments aimed at the underlying genetic causes of human disease

  5. PixarBio Corporation Announces USFDA OPD Submission Of NeuroRelease TN For Orphan Drug Designation For Trigeminal Neuralgia

    PixarBio Corporation recently announced that it has filed an application with the US FDA Office of Orphan Products Development, for orphan drug status of our NeuroRelease TN (NR-TN) drug candidate for the treatment of Trigeminal Neuralgia (TN)

  6. FDA Advisory Committee Recommends The Approval Of Lesinurad For Gout Patients

    AstraZeneca recently announced that the US Food and Drug Administration’s (FDA) Arthritis Advisory Committee (AAC) voted 10-4 to recommend the approval of lesinurad 200 mg tablets for the treatment of hyperuricemia associated with gout, in combination with a xanthine oxidase inhibitor (XOI)

  7. Acceleron Highlights Phase 3 Studies, New Clinical Results And Research Strategies At Research And Development Day Event

    Acceleron Pharma Inc., a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic candidates that regulate cellular growth and repair, recently announced the phase 3 clinical trial designs for the luspatercept program in myelodysplastic syndromes (“MEDALIST” study) and beta-thalassemia (“BELIEVE” study), phase 1 preliminary results from the ACE-083 program, and its new IntelliTrap drug discovery platform

  8. Reviva Pharmaceuticals Reports RP5063 Positive Efficacy Results For Memory Deficits

    Reviva Pharmaceuticals, Inc., a privately held drug discovery and development company, recently presented new positive preclinical efficacy data for memory deficits at the Society for Neuroscience annual meeting in Chicago

  9. Lilly And AstraZeneca Expand Immuno-Oncology Research Collaboration With New Combinations

    Eli Lilly and Company (NYSE: LLY) and AstraZeneca (NYSE:AZN) today announced an extension to their existing immuno-oncology collaboration exploring novel combination therapies for the treatment of patients with solid tumors.

  10. Bruker Introduces The Molecular Drug Imager Solution For Small Molecule Drug Discovery And Development

    At the 10th International Society for the Study of Xenobiotics (ISSX) meeting, Bruker recently announced the novel Molecular Drug Imager solution for pre-clinical drug and metabolite imaging